Close Menu

NEW YORK (GenomeWeb) – Beam Therapeutics announced today that it has launched with $87 million in Series A funding to develop precision genetic medicines that make edits to individual base pairs in the genome.

The funding round was led by F-Prime Capital Partners and ARCH Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.